Evaluation of Reference variability [Design Issues]

posted by Helmut Homepage – Vienna, Austria, 2010-03-16 16:01 (3850 d 12:38 ago) – Posting: # 4921
Views: 2,053

Dear Marcel!

» My apologies for dragging this replicate skeleton out of the closet when it seemed like it was comfortably resting.

No problem - if you think we need some more forensics, go for exhumation!

» Was there any mention at this meeting as to whether the results of a replicate design study (finding of intra-subject variablility exceeding 30%) with a lower strength can be used to justify widen acceptance limits for a higher strength of the same drug to undergo a standard BE study?

No. Or to be more precise, nobody asked that question, but I would bet the answer would have been a straight "No!" as well.

» If this is not allowed, can someone explain why not?

I would say there are two reasons.

Dif-tor heh smusma 🖖
Helmut Schütz
[image]

The quality of responses received is directly proportional to the quality of the question asked. 🚮
Science Quotes

Complete thread:

Activity
 Admin contact
21,086 posts in 4,398 threads, 1,468 registered users;
online 7 (0 registered, 7 guests [including 1 identified bots]).
Forum time: Wednesday 05:40 CEST (Europe/Vienna)

When puzzled, it never hurts to read the primary documents 
a rather simple and self-evident principle that has, nonetheless,
completely disappeared from large sectors
of the American experience.    Stephen Jay Gould

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5